{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:12:22Z","timestamp":1770750742905,"version":"3.50.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA184228"],"award-info":[{"award-number":["CA184228"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA274271"],"award-info":[{"award-number":["CA274271"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nucmedbio.2025.109028","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T18:44:06Z","timestamp":1746989046000},"page":"109028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: A simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands"],"prefix":"10.1016","volume":"146-147","author":[{"given":"Truc T.","family":"Huynh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesan","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109028_bb0005","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-017-3665-9","article-title":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"99mTc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2967\/jnumed.112.111203","article-title":"First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer","volume":"54","author":"Barrett","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0050","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0055","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110560","article-title":"The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research","volume":"11","author":"Ruigrok","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0070","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.bioconjchem.7b00458","article-title":"Improving the imaging contrast of 68Ga-PSMA-11 by targeted linker design: charged spacer moieties enhance the pharmacokinetic properties","volume":"28","author":"Baranski","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0075","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acs.molpharmaceut.9b01179","article-title":"Development of 18F-fluoroglycosylated PSMA-ligands with improved renal clearance behavior","volume":"17","author":"Potemkin","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nucmedbio.2018.05.002","article-title":"Brush border enzyme-cleavable linkers: evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors","volume":"62-63","author":"Vaidyanathan","year":"2018","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0085","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0090","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","article-title":"Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer","volume":"49","author":"Tschan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/acs.molpharmaceut.9b00788","article-title":"Cellular delivery of bioorthogonal pretargeting therapeutics in PSMA-positive prostate cancer","volume":"17","author":"Hapuarachchige","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12951-024-02312-y","article-title":"A proof-of-concept study on bioorthogonal-based pretargeting and signal amplify radiotheranostic strategy","volume":"22","author":"Yang","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","article-title":"Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the mass effect","volume":"58","author":"Nicolas","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0110","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-15-0552","article-title":"A phase I\/II study for analytic validation of 89Zr-J591 ImmunoPET as a molecular imaging agent for metastatic prostate cancer","volume":"21","author":"Pandit-Taskar","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0115","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0120","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","article-title":"A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals","volume":"48","author":"Kalidindi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108916","article-title":"A third generation PSMA-targeted agent [211At]YF2: synthesis and in vivo evaluation","volume":"134-135","author":"Feng","year":"2024","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","article-title":"Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy","volume":"48","author":"Ruigrok","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0135","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","article-title":"177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy","volume":"46","author":"Banerjee","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MNM.0000000000001658","article-title":"Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry","volume":"44","author":"Uijen","year":"2023","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2967\/jnumed.121.262098","article-title":"An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy","volume":"63","author":"Mease","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0150","first-page":"1508","article-title":"High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use","volume":"42","author":"Zalutsky","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb3000","doi-asserted-by":"crossref","first-page":"108913","DOI":"10.1016\/j.nucmedbio.2024.108913","article-title":"PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics","volume":"134","author":"Huynh","year":"2024","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","article-title":"A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals","volume":"71","author":"Sharma","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0160","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2967\/jnumed.118.215350","article-title":"Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model","volume":"59","author":"Rousseau","year":"2018","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2025.109028_bb0165","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.120.257931","article-title":"The impact of monosodium glutamate on 68Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled imaging study","volume":"62","author":"Armstrong","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.114.147181","article-title":"PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0175","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0180","first-page":"528","article-title":"Effect of specific activity on the uptake of [68Ga]-DKFZ-PSMA11 in tumor and other organs","volume":"57","author":"Pillarsetty","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0185","first-page":"610","article-title":"Cyclotron produced 68Ga for PET imaging of prostate cancer","volume":"59","author":"Ahad","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0190","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/acsptsci.4c00637","article-title":"Single-photon emission computer tomography imaging of prostate-specific membrane antigen (PSMA) expression in prostate cancer patients using a novel peptide-based probe [99mTc]Tc-BQ0413 with picomolar affinity to PSMA: a phase I\/II clinical study","volume":"8","author":"Medvedeva","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s003350010240","article-title":"Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen\/NAALADase\/folate hydrolase","volume":"12","author":"Bacich","year":"2001","journal-title":"Mamm Genome"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0200","first-page":"284","article-title":"Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents","volume":"35","author":"Roy","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0205","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pros.20413","article-title":"Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human","volume":"66","author":"Aggarwal","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0210","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0215","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0092-8674(92)90636-Q","article-title":"A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains","volume":"69","author":"Letourneur","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.nucmedbio.2025.109028_bb0220","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512500037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512500037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:44:13Z","timestamp":1756154653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980512500037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"alternative-id":["S096980512500037X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109028","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: A simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109028"}}